Adaptive licensing will fail if HTA bodies don't get on board, says Dutch reimbursement committee
This article was originally published in Scrip
The European Medicine's Agency's plans for adaptive licensing are doomed to fail if Europe's health technology appraisal authorities do not get on board, according to Dr Martin van der Graaff from the CVZ, the influential Dutch authority that gives advice on the products that health insurers should reimburse. However, these agencies are not yet an integral part of the discussions, he said.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.